BEIJING – Shanghai-based bispecifc antibody startup Epimab Biotherapeutics Inc. entered a research collaboration and license agreement with Brisbane, Australia-based QIMR Berghofer Medical Research Institute to look for novel bispecific target combinations, a move that could expand the startup’s pipeline.
BEIJING – Nanobody startup Sysvax Inc. is developing a recombinant protein vaccine and a nanobody therapeutic for COVID-19, while trying to extend the half-life of potential COVID-19 treatments with its expertise in this smallest possible antibody format.
HONG KONG – Not even the 9,500 kilometers between Cambridge, U.K., and Tokyo, or the ongoing COVID-19 pandemic, could prevent Japan’s Astellas Pharma Inc. from completing its acquisition of Cambridge-based Nanna Therapeutics Ltd. in a £12 million (US$14.78 million) deal.
LONDON – Leading genome sequencing groups are launching the first meta-analysis in the hunt for genetic factors that explain why some people have worse COVID-19 symptoms than others, after agreeing to share patient sequence data from around the world. The COVID-19 Host Genetics Initiative (CHGI), set up by scientists at the Institute for Molecular Medicine Finland (FIMM), now includes 151 registered studies that are searching for genetic variation associated with severity and outcomes.
Weeks after raising an oversubscribed $60 million series A, Affinia Therapeutics Inc., of Waltham, Mass., is collaborating with Vertex Pharmaceuticals Inc. in a far larger deal, one potentially worth more than $1.6 billion.
HONG KONG – Not even the 9,500 kilometers between Cambridge, U.K., and Tokyo, or the ongoing COVID-19 pandemic, could prevent Japan’s Astellas Pharma Inc. from completing its acquisition of Cambridge-based Nanna Therapeutics Ltd. in a £12 million (US$14.78 million) deal.
Supernus Pharmaceuticals Inc. has struck an agreement with privately held Navitor Pharmaceuticals Inc. to run a joint phase II program for Navitor's mTORC1 activator, NV-5138, in treatment-resistant depression (TRD).
BEIJING – Nanobody startup Sysvax Inc., with its R&D center in Beijing and manufacturing facilities in Zhongshan, is developing a recombinant protein vaccine and a nanobody therapeutic for COVID-19, while trying to extend the half-life of potential COVID-19 treatments with its expertise in this smallest possible antibody format.
Leo Pharma A/S, of Ballerup, Denmark, has eyed a stronger company presence in Asia during the past year and took a giant step to achieving it by signing a worldwide exclusive licensing agreement with Oneness Biotech Co. Ltd., of Taipei, Taiwan, and Microbio Shanghai Co. Ltd. to develop and commercialize FB-825 for treating atopic dermatitis and allergic asthma.
Biofourmis Inc. has acquired Los Angeles-based Gaido Health from Takeda Pharmaceuticals in a move designed to significantly expand the company's oncology offerings. Gaido Health's solution will be integrated into Boston-based Biofourmis' Biovitals platform, enhancing its ability to remotely monitor oncology patients at home using a single sensor.
RSS
